GSK plc announced the FDA expanded the approval of Jemperli (dostarlimab) plus chemotherapy to all adults with advanced or recurrent endometrial cancer on August 1, 2024, demonstrating a 31% reduction in death risk, providing hope for 70-75% of patients with limited options. The filing is significant for the company as it enhances treatment options for a large patient population.